S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
91. Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN, Scardino PT. Combined
endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in
prostate cancer. AJR Am J Roentgenol 2006;186(3):743-8.
http://www.ncbi.nlm.nih.gov/pubmed/16498101
92. Park BK, Kim B, Kim CK, Lee HM, Kwon GY. Comparison of phased-array 3.0-T and
endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for
prostate cancer. J Comput Assist Tomogr 2007;31(4):534-8.
http://www.ncbi.nlm.nih.gov/pubmed/17882027
93. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN,
Thalmann GN. The Role of Choline Positron Emission Tomography/Computed Tomography
in the Management of Patients with Prostate-Specific Antigen Progression After Radical
Treatment of Prostate Cancer. Eur Urol 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20869161
94. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL. The 2005 International Society of
Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic
Carcinoma. Am J Surg Pathol 2005;29(9):1228-42.
http://www.ncbi.nlm.nih.gov/pubmed/16096414
95. Wittekind C, Klimpfinger M, Sobin LH. TNM-Atlas. 5th ed. Berlin: Springer; 2011.
96. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia
or atypical foci suspicious for carcinoma: implications for patient care. Journal of Urology
2006;175(3 Pt 1):820-34. http://www.ncbi.nlm.nih.gov/pubmed/16469560
97. Schlesinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intraepithelial neoplasia
and atypical small acinar proliferation: predictive value for cancer in current practice. Am J
Surg Pathol 2005;29(9):1201-7. http://www.ncbi.nlm.nih.gov/pubmed/16096410
98. Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP, Jr., Mian BM. Prognostic
significance of high grade prostatic intraepithelial neoplasia and atypical small acinar
proliferation in the contemporary era. Journal of Urology 2005;173(1):70-2.
http://www.ncbi.nlm.nih.gov/pubmed/15592031
99. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and
neoplastic human prostate. Cancer Res 1985;45(8):3663-7.
http://www.ncbi.nlm.nih.gov/pubmed/2410099
100. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins:
patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31(1):11-
24. http://www.ncbi.nlm.nih.gov/pubmed/6186379
101. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific
markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol
2002;26(9):1161-8. http://www.ncbi.nlm.nih.gov/pubmed/12218572
102. Wernert N, Seitz G, Achtstatter T. Immunohistochemical investigation of different
cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in
prostate carcinoma. Pathol Res Pract 1987;182(5):617-26.
http://www.ncbi.nlm.nih.gov/pubmed/2446293
103. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, (eds.). World Health Organisation Classification
for Tumours. Pathology & Genetics. Tumours of the Urinary System and Male Genital
Organs. Lyon: IARC Pr.; 2004.
104. Netto GJ, Epstein JI. Widespread high-grade prostatic intraepithelial neoplasia on prostatic
needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma. Am J
Surg Pathol 2006;30(9):1184-8. http://www.ncbi.nlm.nih.gov/pubmed/16931964
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011